Mylan Chairman Robert Coury knows rejection but also the value of persistence. Four months after being spurned by Perrigo shareholders, he has a $7.2 billion deal to buy Sweden's Meda, a company that two years ago rejected an earlier Mylan proposal.
Pfizer's planned $160 billion merger with Allergan has some researchers worried the company will embrace its counterpart's austere approach to R&D and mount major layoffs.
After months of agitating and activism from miffed shareholders, Astellas has finally convinced the majority of Ocata Therapeutics investors to accept its $8.50-a-share offer, ending a surprisingly protracted process for the Japanese drugmaker.
Hikma Pharmaceuticals said last year that it would shell out more than $1 billion for Boehringer Ingelheim's U.S.-based generics business, Roxane Labs, to gain ground in noninjectable generics. But now, Hikma is slashing its offer price for the deal after catching wind of Roxane's disappointing 2015 sales.
One of the market themes that emerged in 2015 was that marquee biotech players could get a boost out of a high-profile acquisition--just as Big Pharmas remained aloof to the ever-rising, jaw-dropping price tags tied to drug pipelines after a three-year bull market. Now, though, with industry share prices in a savage spiral, some top execs in the industry voted most likely to ink new deals are adopting a wary attitude as they wait for the dust to settle.
Actelion, the standard bearer in treatments for pulmonary arterial hypertension, is scouting for new disease areas as it rolls out its next potential blockbuster, hoping to keep up its pace of growth by pivoting away from its home base.
Abbott's just-announced acquisition of ablation catheter player Kalila Medical reflects the growing adoption of interventional electrophysiology and other devices to treat atrial fibrillation and stroke.
Former Covidien head Jose Almeida, who seized the reins at Baxter at the start of the year, offered an early glimpse of his long-term strategy for the company after spinning off the biopharma Baxalta last year. On a Feb. 2 earnings call, he laid out his priorities as trimming operating expenses, reallocating capital to support innovation and growth, and making smaller acquisitions.
As healthcare providers call for more technology to improve efficiencies, some of the device industry's biggest players are stepping forward with deals aimed at speeding up services and reducing costs.
Hot on the trail of dental device acquisitions, dental implant giants Straumann and Dentsply International are reportedly weighing a deal for Israel's MIS Implants Technologies.